Global longitudinal strain is superior to ejection fraction for detecting myocardial dysfunction in end-stage renal disease with hyperparathyroidism.

Maria Fernanda Carrasco-Ruiz, Antonio Ruiz-Rivera, Marvin A Soriano-Ursúa, Carlos Martinez-Hernandez, Leticia Manuel-Apolinar, Carmen Castillo-Hernandez, Gustavo Guevara-Balcazar, Eunice D Farfán-García, Ana Mejia-Ruiz, Ivan Rubio-Gayosso, Teresa Perez-Capistran
Author Information
  1. Maria Fernanda Carrasco-Ruiz: Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  2. Antonio Ruiz-Rivera: Department of Cardiology, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico.
  3. Marvin A Soriano-Ursúa: Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  4. Carlos Martinez-Hernandez: Department of Cardiology, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico.
  5. Leticia Manuel-Apolinar: Endocrine Research Unit, Instituto Mexicano del Seguro Social, Ciudad de México 06720, Mexico.
  6. Carmen Castillo-Hernandez: Department of Cardiovascular Pharmacology, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  7. Gustavo Guevara-Balcazar: Department of Cardiovascular Pharmacology, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  8. Eunice D Farfán-García: Department of Biochemistry, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  9. Ana Mejia-Ruiz: Education Research, Comisión Nacional Para la Mejora Continua de la Educación, Ciudad de México 03900, Mexico.
  10. Ivan Rubio-Gayosso: Postgraduate Studies and Research Section,Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.
  11. Teresa Perez-Capistran: Department of Physiology, Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de México 11340, Mexico.

Abstract

BACKGROUND: The estimation of left ventricular ejection fraction (LVEF) by 2D echocardiography (2D-ECHO) is the most used tool to assess LV systolic function (LVSF). Global longitudinal strain (GLS) has recently been suggested as a superior method for several evaluations. This study explored the association and prevalence of LV systolic dysfunction (LVSD) by using these methods in patients with end-stage renal disease (ESRD) and severe hyperparathyroidism (SHPTH); both associated with cardiovascular events (CEs).
AIM: To evaluate the myocardial function in patients with ESRD and SHPTH by using the GLS and LVEF measured through conventional 2D-ECHO.
METHODS: In 62 patients with ESRD and SHPTH, asymptomatic, and without a history of CEs, LVSF was evaluated by 2D-ECHO, obtaining the EF, by the Simpson biplane method, and GLS by speckle tracking.
RESULTS: The total patients with ESRD had a preserved LVEF (> 50%) but abnormal GLS (< 13.55%). Additionally, multivariate analysis showed an independent association of GLS and serum parathyroid hormone (PTH), LV mass index, and hemoglobin. Also, PTH was independently associated with lateral e' wave and tricuspid regurgitation velocity.
CONCLUSION: In patients with SHPTH linked to ESRD, the use of GLS by 2D-ECHO is a more sensitive tool than LVEF for detecting LVSD.

Keywords

References

  1. Nephrol Dial Transplant. 2001 Jul;16(7):1459-64 [PMID: 11427641]
  2. Eur J Endocrinol. 2017 Jan;176(1):R39-R52 [PMID: 27601015]
  3. PLoS One. 2018 Oct 16;13(10):e0205848 [PMID: 30325973]
  4. Mayo Clin Proc. 2001 Nov;76(11):1111-9 [PMID: 11702899]
  5. Cardiorenal Med. 2015 Oct;5(4):254-66 [PMID: 26648942]
  6. PLoS One. 2019 Jan 16;14(1):e0209578 [PMID: 30650094]
  7. Clin Exp Nephrol. 2017 Mar;21(Suppl 1):53-63 [PMID: 28062938]
  8. J Am Coll Cardiol. 2002 Feb 20;39(4):695-701 [PMID: 11849871]
  9. J Am Soc Echocardiogr. 2018 Nov;31(11):1203-1208 [PMID: 30241926]
  10. Eur Heart J. 2016 Mar 7;37(10):811-6 [PMID: 26685140]
  11. Nephrol Dial Transplant. 2009 Jan;24(1):34-7 [PMID: 19028753]
  12. Cell Mol Life Sci. 2011 Jan;68(1):1-13 [PMID: 20703892]
  13. Eur J Heart Fail. 2018 Mar;20(3):560-568 [PMID: 29164753]
  14. Cardiol Young. 2021 Mar;31(3):421-428 [PMID: 33308338]
  15. J Am Soc Nephrol. 2006 Jul;17(7):2034-47 [PMID: 16738019]
  16. J Clin Endocrinol Metab. 2015 Dec;100(12):4399-407 [PMID: 26445115]
  17. Ther Apher Dial. 2018 Jun;22(3):236-241 [PMID: 29707916]
  18. Hypertension. 2009 Oct;54(4):818-24 [PMID: 19635983]
  19. Front Physiol. 2019 Mar 01;10:159 [PMID: 30881310]
  20. Eur J Heart Fail. 2010 Aug;12(8):805-11 [PMID: 20494923]
  21. J Am Heart Assoc. 2020 Jun 16;9(12):e015009 [PMID: 32519555]
  22. J Am Heart Assoc. 2018 Sep 18;7(18):e008334 [PMID: 30371180]
  23. Int J Biol Sci. 2011;7(7):1056-67 [PMID: 21927575]
  24. Lancet. 2013 Jul 27;382(9889):339-52 [PMID: 23727170]
  25. J Clin Hypertens (Greenwich). 2020 Apr;22(4):683-685 [PMID: 32073217]
  26. Quant Imaging Med Surg. 2021 May;11(5):1899-1908 [PMID: 33936973]
  27. Nephron Clin Pract. 2012;120(4):c179-84 [PMID: 22890468]
  28. Echocardiography. 2020 Nov;37(11):1919-1925 [PMID: 32476157]
  29. Front Med (Lausanne). 2018 Jul 24;5:206 [PMID: 30087898]
  30. J Am Heart Assoc. 2018 Oct 2;7(19):e009331 [PMID: 30371332]
  31. Circulation. 2019 Jan 15;139(3):351-361 [PMID: 30586723]
  32. Toxins (Basel). 2020 Mar 05;12(3): [PMID: 32150864]
  33. Echocardiography. 2020 Nov;37(11):1784-1791 [PMID: 33084159]
  34. J Mol Cell Cardiol. 2011 Oct;51(4):600-6 [PMID: 21059352]
  35. Nephrol Dial Transplant. 2012 Apr;27(4):1437-45 [PMID: 21825304]
  36. Rev Esp Cardiol (Engl Ed). 2015 Apr;68(4):331-7 [PMID: 25743769]
  37. J Am Soc Nephrol. 2001 Jul;12(7):1508-1515 [PMID: 11423580]
  38. J Clin Invest. 2011 Nov;121(11):4393-408 [PMID: 21985788]
  39. Trends Pharmacol Sci. 2012 Aug;33(8):423-31 [PMID: 22709554]
  40. Growth Factors. 2011 Oct;29(5):196-202 [PMID: 21740331]
  41. Nephrology (Carlton). 2016 Feb;21(2):133-8 [PMID: 26199009]
  42. J Vet Emerg Crit Care (San Antonio). 2013 Mar-Apr;23(2):134-62 [PMID: 23566108]
  43. Am J Cardiol. 2013 Feb 1;111(3):418-24 [PMID: 23168286]
  44. Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):992-9 [PMID: 25733208]
  45. Eur Heart J Cardiovasc Imaging. 2015 May;16(5):539-48 [PMID: 25428945]
  46. PLoS One. 2016 Jul 11;11(7):e0156860 [PMID: 27400031]
  47. J Nephrol. 2015 Dec;28(6):729-37 [PMID: 25708914]
  48. Clin Kidney J. 2020 Jun 26;13(3):307-321 [PMID: 32699616]
  49. Kidney Int. 2001 Apr;59(4):1559-66 [PMID: 11260421]
  50. J Am Soc Echocardiogr. 2010 Apr;23(4):351-69; quiz 453-5 [PMID: 20362924]
  51. Medicina (Kaunas). 2018 Nov 13;54(5): [PMID: 30428607]
  52. Biomed Pharmacother. 2018 May;101:670-681 [PMID: 29518614]
  53. Eur Heart J. 2021 Feb 14;42(7):789-797 [PMID: 32974648]

Word Cloud

Created with Highcharts 10.0.0GLSpatientsESRDLVEF2D-ECHOSHPTHLVGloballongitudinalstraindysfunctionrenaldiseaseventricularejectionfractiontoolsystolicfunctionLVSFsuperiormethodassociationLVSDusingend-stagehyperparathyroidismassociatedCEsmyocardialPTHdetectingBACKGROUND:estimationleft2DechocardiographyusedassessrecentlysuggestedseveralevaluationsstudyexploredprevalencemethodsseverecardiovasculareventsAIM:evaluatemeasuredconventionalMETHODS:62asymptomaticwithouthistoryevaluatedobtainingEFSimpsonbiplanespeckletrackingRESULTS:totalpreserved>50%abnormal<1355%AdditionallymultivariateanalysisshowedindependentserumparathyroidhormonemassindexhemoglobinAlsoindependentlylaterale'wavetricuspidregurgitationvelocityCONCLUSION:linkedusesensitiveEnd-stageLefthypertrophyParathormoneSystolic

Similar Articles

Cited By